← Назад

Takayasu arteritis

ORPHA:3287DiseaseNot applicableAdolescent, Adult

Ассоциированные гены (3)

HLA-B
major histocompatibility complex, class I, B
Major susceptibility factor in
OMIM: 142830
IL12B
interleukin 12B
Major susceptibility factor in
OMIM: 161561
MLX
MAX dimerization protein MLX
Major susceptibility factor in
OMIM: 602976

Фенотипы (54)

Очень частый (80–99%)9
HP:0001654Abnormal heart valve morphology
HP:0001824Weight loss
HP:0001945Fever
HP:0002617Dilatation
HP:0002633Vasculitis
HP:0012089Arteritis
HP:0012378Fatigue
HP:0100545Arterial stenosis
HP:0100735Hypertensive crisis
Частый (30–79%)24
HP:0000822Hypertension
HP:0001250Seizure
HP:0001324Muscle weakness
HP:0001369Arthritis
HP:0001646Abnormal aortic valve morphology
HP:0001658Myocardial infarction
HP:0001903Anemia
HP:0001920Renal artery stenosis
HP:0002039Anorexia
HP:0002076Migraine
HP:0002092Pulmonary arterial hypertension
HP:0002315Headache
HP:0003326Myalgia
HP:0003565Elevated erythrocyte sedimentation rate
HP:0004417Intermittent claudication
HP:0004970Ascending tubular aorta aneurysm
HP:0012649Increased inflammatory response
HP:0020141Blood pressure substantially higher in legs than arms
HP:0032554Absent pulse
HP:0100749Chest pain
HP:0100758Gangrene
HP:0200042Skin ulcer
HP:6000944Carotidynia
HP:6000945Asymmetric blood pressure between arms
Периодический (5–29%)21
HP:0000488Retinopathy
HP:0000505Visual impairment
HP:0001297Stroke
HP:0001635Congestive heart failure
HP:0001644Dilated cardiomyopathy
HP:0001659Aortic regurgitation
HP:0002094Dyspnea
HP:0002105Hemoptysis
HP:0002167Abnormality of speech or vocalization
HP:0002321Vertigo
HP:0002326Transient ischemic attack
HP:0002637Cerebral ischemia
HP:0002829Arthralgia
HP:0004306Abnormality of the endocardium
HP:0004372Reduced consciousness/confusion
HP:0005244Gastrointestinal infarctions
HP:0011227Elevated circulating C-reactive protein concentration
HP:0012219Erythema nodosum
HP:0030166Night sweats
HP:0033834Malaise
HP:0100576Amaurosis fugax

Эпидемиология (21)

Annual incidence
<1 / 1 000 000
Europe
Point prevalence
1-9 / 100 000
Europe
Annual incidence
<1 / 1 000 000
United Kingdom
Point prevalence
1-9 / 100 000
Japan
Annual incidence
1-9 / 1 000 000
Sweden
Point prevalence
1-9 / 1 000 000
Sweden
Point prevalence
1-9 / 1 000 000
United Kingdom
Annual incidence
<1 / 1 000 000
Denmark
Point prevalence
1-9 / 100 000
Worldwide
Annual incidence
<1 / 1 000 000
Germany
Point prevalence
1-9 / 1 000 000
Kuwait
Annual incidence
1-9 / 1 000 000
Japan
Annual incidence
1-9 / 1 000 000
Lithuania
Annual incidence
1-9 / 1 000 000
Kuwait
Annual incidence
1-9 / 1 000 000
United States
Annual incidence
1-9 / 1 000 000
Norway
Point prevalence
1-9 / 100 000
Norway
Point prevalence
1-9 / 100 000
Korea, Republic of
Annual incidence
1-9 / 1 000 000
Korea, Republic of
Point prevalence
1-9 / 1 000 000
Poland
Annual incidence
<1 / 1 000 000
Poland

Лекарства и терапия

Источник: Open Targets Platform (в реальном времени)

Клинические исследования

Источник: ClinicalTrials.gov (в реальном времени)

Внешние ресурсы